Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04688658 · ClinicalTrials.gov registry record · Phase 1
Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable Melanoma
A Phase 1 study, sponsored by John Kirkwood.
- Terminated
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT04688658 is a Phase 1 study that was terminated before completion, run by John Kirkwood. The registered enrollment target is 13 participants.
The verdict
NCT04688658, a Phase 1 study, was terminated before completion, sponsored by John Kirkwood.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
This trial is a Phase I/II study in which a combination of duvelisib and nivolumab will be used to treat a total of patients diagnosed with advanced unresectable melanoma who have progressed on anti-PD1 therapy. The Recommended Phase II Dose of oral duvelisib will be determined and administered with intravenous nivolumab 480mg for up to 1 year or until the patient's disease does not progress or the patient experiences unacceptable side effects to treatment.
Interventions
- DRUG Nivolumab
- DRUG Duvelisib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2021-10-06 |
| Est. Completion | 2025-02-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04688658
The ClinicalTrials.gov registry entry for NCT04688658 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is John Kirkwood, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nivolumab is the first listed.
NCT04688658 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04688658 about?
NCT04688658 is a clinical study titled "Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable Melanoma". This trial is a Phase I/II study in which a combination of duvelisib and nivolumab will be used to treat a total of patients diagnosed with advanced unresectable melanoma who have progressed on anti-PD1 therapy. The Recommended Phase II Dose of oral duvelisib will be determined and administered with...
What is the current status of trial NCT04688658?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2021-10-06. Estimated completion is 2025-02-01.
What interventions are being tested in trial NCT04688658?
The interventions under investigation include: Nivolumab (DRUG), Duvelisib (DRUG).
Who is sponsoring clinical trial NCT04688658?
This trial is sponsored by John Kirkwood, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.